Premium
Histamine‐2 (H 2 ) antagonists can be safely removed from standard paclitaxel premedication regimens
Author(s) -
Foreman Emma,
Polwart Calum,
Walker Andrew,
Chambers Pinkie
Publication year - 2022
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.15363
Subject(s) - premedication , paclitaxel , pharmacology , histamine , medicine , anesthesia , chemotherapy
Aims The aim of this study is to investigate the rates of hypersensitivity reactions (HSRs) in patients receiving paclitaxel chemotherapy, with and without a histamine‐2 (H 2 ) antagonists. Method This prospective, multi‐centre, cohort study compared patients receiving paclitaxel treated with premedication regimens containing chlorphenamine, dexamethasone and an H 2 antagonist vs patients treated without an H 2 antagonist. Rates of HSRs were described and logistic multivariable regression was used to investigate any associations with H 2 antagonist treatment, adjusting for confounding variables. Results A total of 1043 individuals were included in the study; of these, 638 (61%) patients received an H 2 antagonist and 405 (49%) were not given an H 2 antagonist. Incidence of HSR in the cohort treated with H 2 antagonists was 11.31% ( n = 70) vs 9.86% ( n = 41) in the cohort without. There was no statistically significant difference between the rates of HSR observed in those receiving and not receiving an H 2 antagonist (odds ratio 1.04, 95% CI 0.65, 1.66, P = .9). Conclusions Results presented within the study are consistent with other recently published evidence to suggest that H 2 antagonists do not confer any advantage as part of premedication regimens in reducing the incidence of HSR in patients treated with paclitaxel.